228 related articles for article (PubMed ID: 17018628)
1. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.
Ansiaux R; Baudelet C; Jordan BF; Crokart N; Martinive P; DeWever J; Grégoire V; Feron O; Gallez B
Cancer Res; 2006 Oct; 66(19):9698-704. PubMed ID: 17018628
[TBL] [Abstract][Full Text] [Related]
2. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption.
Jordan BF; Grégoire V; Demeure RJ; Sonveaux P; Feron O; O'Hara J; Vanhulle VP; Delzenne N; Gallez B
Cancer Res; 2002 Jun; 62(12):3555-61. PubMed ID: 12068004
[TBL] [Abstract][Full Text] [Related]
3. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.
Ansiaux R; Baudelet C; Jordan BF; Beghein N; Sonveaux P; De Wever J; Martinive P; Grégoire V; Feron O; Gallez B
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):743-50. PubMed ID: 15701864
[TBL] [Abstract][Full Text] [Related]
5. Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect.
Crokart N; Radermacher K; Jordan BF; Baudelet C; Cron GO; Grégoire V; Beghein N; Bouzin C; Feron O; Gallez B
Cancer Res; 2005 Sep; 65(17):7911-6. PubMed ID: 16140962
[TBL] [Abstract][Full Text] [Related]
6. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line.
Schuuring J; Bussink J; Bernsen HJ; Peeters W; van Der Kogel AJ
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):529-34. PubMed ID: 15667976
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
8. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
[TBL] [Abstract][Full Text] [Related]
9. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
10. Combined antiangiogenic and immune therapy of prostate cancer.
Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
[TBL] [Abstract][Full Text] [Related]
11. Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions.
Crokart N; Jordan BF; Baudelet C; Ansiaux R; Sonveaux P; Grégoire V; Beghein N; DeWever J; Bouzin C; Feron O; Gallez B
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):901-10. PubMed ID: 16199320
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
[TBL] [Abstract][Full Text] [Related]
13. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
Dowlati A; Robertson K; Radivoyevitch T; Waas J; Ziats NP; Hartman P; Abdul-Karim FW; Wasman JK; Jesberger J; Lewin J; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2005 Nov; 11(21):7938-44. PubMed ID: 16278419
[TBL] [Abstract][Full Text] [Related]
14. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy.
Griffin RJ; Williams BW; Park HJ; Song CW
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1516-22. PubMed ID: 15817358
[TBL] [Abstract][Full Text] [Related]
15. Reduced tumor oxygenation by treatment with vinblastine.
Sersa G; Krzic M; Sentjurc M; Ivanusa T; Beravs K; Cemazar M; Auersperg M; Swartz HM
Cancer Res; 2001 May; 61(10):4266-71. PubMed ID: 11358854
[TBL] [Abstract][Full Text] [Related]
16. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
Fenton BM; Paoni SF
Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
[TBL] [Abstract][Full Text] [Related]
17. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
18. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Overmoyer B; Fu P; Hoppel C; Radivoyevitch T; Shenk R; Persons M; Silverman P; Robertson K; Ziats NP; Wasman JK; Abdul-Karim FW; Jesberger JA; Duerk J; Hartman P; Hanks S; Lewin J; Dowlati A; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2007 Oct; 13(19):5862-8. PubMed ID: 17908980
[TBL] [Abstract][Full Text] [Related]
20. EPR oximetry of tumors in vivo in cancer therapy.
Sentjurc M; Cemazar M; Sersa G
Spectrochim Acta A Mol Biomol Spectrosc; 2004 May; 60(6):1379-85. PubMed ID: 15134738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]